RxDoctor Payments Data

Edmund Concepcion, PA

Physician Assistant · San Diego, CANPI 1922528280

Payments from drug & device makers

$334in general payments, 2019–2025

Across 17 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$119
  • AbbVie$63
  • Endo Pharmaceuticals Inc.$60
  • Endo USA, Inc.$56
  • ABC Home Medical Supply, Inc.$19
  • Teva Pharmaceuticals USA, Inc.$18

What the payments were for

  • Food & beverage$334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sumitomo Pharma America, Inc.6$119
AbbVie3$63
Endo Pharmaceuticals Inc.3$60
Endo USA, Inc.3$56
ABC Home Medical Supply, Inc.1$19
Teva Pharmaceuticals USA, Inc.1$18

How this compares

$334 in reported general payments places this provider in the 55th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$77,070
Medicare patients
301
Services billed
9,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron43$43,819
GemtesaVibegron23$28,056
Estradiol76$5,579
Tamsulosin Hcl208$2,968
Testosterone22$2,506
Methenamine Hippurate20$2,078
Testosterone Cypionate38$1,712
Alfuzosin Hcl ErAlfuzosin Hcl55$1,409
Finasteride69$1,021
Ciprofloxacin Hcl13$91
Cephalexin17$70
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$46
Anastrozole20$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$119$28,05623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,423 physician assistant providers in California.

Other physician assistant in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →